NFE2L2 and myeloid sarcoma: A phase 3 clinical trial for MS demonstrated that oral treatment with delayed-release dimethyl fumarate (DMF) was effective in activating NRF2, but further studies are needed to determine if GSH levels were increased and if MS could be delayed following DMF treatment (155).